Racial Disparities in Prostate Ca Recurrence
Black men are more likely than white men to have a prostate cancer recurrence after radical prostatectomy, Hadley M. Wood, MD, reported at the 2006 Prostate Cancer Symposium (abstract 138).
SAN FRANCISCOBlack men are more likely than white men to have a prostate cancer recurrence after radical prostatectomy, Hadley M. Wood, MD, reported at the 2006 Prostate Cancer Symposium (abstract 138). Dr. Wood is a resident at the Glickman Urological Institute of the Cleveland Clinic Foundation. This prospective study assessed biochemical failure rates in 2,910 men of both races during two time periods: the "early PSA period" (1987-1997) and the "later PSA period" (1998-2004). The men were followed for at least 12 months after surgery, with biochemical failure defined as PSA more than 0.2 ng/mL. Both groups were more likely to have organ-confined disease during the later PSA period; rates increased from 54% in the early period to 76% in the later period for black men (P = .0001) and from 50% to 71% for white men (P < .0001). Progression-free survival (PFS) at 5 years increased in both groups between the two periods, from 67% to 71% for blacks and from 78% to 82% for whites. The difference in PFS between the races, however, remained constant at 11% during both periods. Dr. Wood said this difference occurred even though black men were more likely to have organ-confined disease, and both groups had similar Gleason scores, clinical T stage, and initial PSA level.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
